Does the media prefer MDWD or MREO?

In the previous week, MediWound and MediWound both had 3 articles in the media. Mereo BioPharma Group's average media sentiment score of 0.95 beat MediWound's score of 0.45 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mereo BioPharma Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PLX or MREO?

In the previous week, Mereo BioPharma Group had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Mereo BioPharma Group and 2 mentions for Protalix BioTherapeutics. Mereo BioPharma Group's average media sentiment score of 0.95 beat Protalix BioTherapeutics' score of 0.55 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mereo BioPharma Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DTIL or MREO?

In the previous week, Precision BioSciences had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 6 mentions for Precision BioSciences and 3 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.95 beat Precision BioSciences' score of 0.56 indicating that Mereo BioPharma Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mereo BioPharma Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRQR or MREO?

In the previous week, ProQR Therapeutics had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 5 mentions for ProQR Therapeutics and 3 mentions for Mereo BioPharma Group. ProQR Therapeutics' average media sentiment score of 1.55 beat Mereo BioPharma Group's score of 0.95 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Mereo BioPharma Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MREO or VYGR?

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Mereo BioPharma Group and 1 mentions for Voyager Therapeutics. Mereo BioPharma Group's average media sentiment score of 0.95 beat Voyager Therapeutics' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Mereo BioPharma Group (MREO) Competitors

$0.34 -0.01 (-1.96%)

As of 12:44 PM Eastern

Compare

MREO vs. MDWD, PLX, DTIL, PRQR, and VYGR

Should you buy Mereo BioPharma Group stock or one of its competitors? MarketBeat compares Mereo BioPharma Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mereo BioPharma Group include MediWound (MDWD), Protalix BioTherapeutics (PLX), Precision BioSciences (DTIL), ProQR Therapeutics (PRQR), and Voyager Therapeutics (VYGR).

How does Mereo BioPharma Group compare to MediWound?

MediWound (NASDAQ:MDWD) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Mereo BioPharma Group has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

46.8% of MediWound shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, MediWound and MediWound both had 3 articles in the media. Mereo BioPharma Group's average media sentiment score of 0.95 beat MediWound's score of 0.45 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mereo BioPharma Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MediWound has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

MediWound has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.65	-$23.88M	-$2.26	N/A
Mereo BioPharma Group	$500K	107.26	-$41.88M	-$0.05	N/A

MediWound currently has a consensus target price of $34.00, indicating a potential upside of 141.99%. Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 867.26%. Given Mereo BioPharma Group's higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Mereo BioPharma Group beats MediWound on 8 of the 14 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Mereo BioPharma Group has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

In the previous week, Mereo BioPharma Group had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 3 mentions for Mereo BioPharma Group and 2 mentions for Protalix BioTherapeutics. Mereo BioPharma Group's average media sentiment score of 0.95 beat Protalix BioTherapeutics' score of 0.55 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mereo BioPharma Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protalix BioTherapeutics has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.54	$8.31M	$0.18	13.36
Mereo BioPharma Group	$500K	107.26	-$41.88M	-$0.05	N/A

Protalix BioTherapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 399.17%. Mereo BioPharma Group has a consensus price target of $3.25, suggesting a potential upside of 867.26%. Given Mereo BioPharma Group's higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Mereo BioPharma Group beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Precision BioSciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Mereo BioPharma Group has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Mereo BioPharma Group's return on equity of -81.28% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

In the previous week, Precision BioSciences had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 6 mentions for Precision BioSciences and 3 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.95 beat Precision BioSciences' score of 0.56 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mereo BioPharma Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mereo BioPharma Group has lower revenue, but higher earnings than Precision BioSciences. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.07M	4.03	-$45.72M	-$3.67	N/A
Mereo BioPharma Group	$500K	107.26	-$41.88M	-$0.05	N/A

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Precision BioSciences presently has a consensus price target of $32.25, indicating a potential upside of 358.42%. Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 867.26%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Mereo BioPharma Group beats Precision BioSciences on 9 of the 16 factors compared between the two stocks.

How does Mereo BioPharma Group compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

ProQR Therapeutics currently has a consensus target price of $7.33, indicating a potential upside of 325.61%. Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 867.26%. Given Mereo BioPharma Group's higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

ProQR Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 5 mentions for ProQR Therapeutics and 3 mentions for Mereo BioPharma Group. ProQR Therapeutics' average media sentiment score of 1.55 beat Mereo BioPharma Group's score of 0.95 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Mereo BioPharma Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mereo BioPharma Group has lower revenue, but higher earnings than ProQR Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$13.42M	13.53	-$47.73M	-$0.50	N/A
Mereo BioPharma Group	$500K	107.26	-$41.88M	-$0.05	N/A

Mereo BioPharma Group has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Mereo BioPharma Group's return on equity of -81.28% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Summary

ProQR Therapeutics and Mereo BioPharma Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Voyager Therapeutics?

Mereo BioPharma Group (NASDAQ:MREO) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Mereo BioPharma Group has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Mereo BioPharma Group and 1 mentions for Voyager Therapeutics. Mereo BioPharma Group's average media sentiment score of 0.95 beat Voyager Therapeutics' score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Voyager Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mereo BioPharma Group currently has a consensus price target of $3.25, indicating a potential upside of 867.26%. Voyager Therapeutics has a consensus price target of $16.50, indicating a potential upside of 450.92%. Given Mereo BioPharma Group's higher possible upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Mereo BioPharma Group has higher earnings, but lower revenue than Voyager Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	107.26	-$41.88M	-$0.05	N/A
Voyager Therapeutics	$40.37M	4.48	-$119.72M	-$1.97	N/A

Mereo BioPharma Group has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

Summary

Mereo BioPharma Group beats Voyager Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MREO vs. The Competition

Export

Metric	Mereo BioPharma Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$53.63M	$3.52B	$6.79B	$12.63B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-6.72	7.39	282.14	25.05
Price / Sales	107.26	1,212.47	573.43	80.07
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	1.29	17.11	11.09	6.19
Net Income	-$41.88M	-$12.56M	$3.49B	$347.61M
7 Day Performance	11.22%	-0.59%	0.42%	0.74%
1 Month Performance	0.39%	-7.44%	-4.33%	-3.72%
1 Year Performance	-79.76%	49.84%	63.09%	20.27%

Mereo BioPharma Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MREO Mereo BioPharma Group	3.4094 of 5 stars	$0.34 -2.0%	$3.25 +867.3%	-79.4%	$53.79M	$500K	N/A	40	News Coverage
MDWD MediWound	3.3563 of 5 stars	$14.81 +2.5%	$34.00 +129.5%	-23.8%	$190.05M	$16.96M	N/A	80	Positive News
PLX Protalix BioTherapeutics	2.791 of 5 stars	$2.34 -2.7%	$12.00 +413.9%	+63.4%	$187.89M	$76.38M	N/A	200
DTIL Precision BioSciences	2.6346 of 5 stars	$7.14 -1.5%	$32.25 +351.4%	+51.3%	$184.28M	$45.07M	N/A	200	News Coverage Positive News Upcoming Earnings Analyst Forecast
PRQR ProQR Therapeutics	4.1024 of 5 stars	$1.73 -0.3%	$7.33 +325.1%	-17.3%	$181.75M	$13.42M	N/A	180	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MREO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mereo BioPharma Group (MREO) Competitors

MREO vs. MDWD, PLX, DTIL, PRQR, and VYGR

How does Mereo BioPharma Group compare to MediWound?

Summary

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Summary

How does Mereo BioPharma Group compare to Precision BioSciences?

Summary

How does Mereo BioPharma Group compare to ProQR Therapeutics?

Summary

How does Mereo BioPharma Group compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mereo BioPharma Group (MREO) Competitors

MREO vs. MDWD, PLX, DTIL, PRQR, and VYGR

How does Mereo BioPharma Group compare to MediWound?

Is MDWD or MREO more profitable?

Do insiders and institutionals believe in MDWD or MREO?

Does the media prefer MDWD or MREO?

Which has more volatility and risk, MDWD or MREO?

Which has better valuation and earnings, MDWD or MREO?

Do analysts prefer MDWD or MREO?

Summary

How does Mereo BioPharma Group compare to Protalix BioTherapeutics?

Do institutionals & insiders have more ownership in PLX or MREO?

Is PLX or MREO more profitable?

Does the media refer more to PLX or MREO?

Which has higher valuation and earnings, PLX or MREO?

Do analysts rate PLX or MREO?

Summary

How does Mereo BioPharma Group compare to Precision BioSciences?

Which has more volatility & risk, DTIL or MREO?

Is DTIL or MREO more profitable?

Does the media prefer DTIL or MREO?

Which has preferable valuation & earnings, DTIL or MREO?

Do institutionals & insiders believe in DTIL or MREO?

Do analysts prefer DTIL or MREO?

Summary

How does Mereo BioPharma Group compare to ProQR Therapeutics?

Do analysts rate PRQR or MREO?

Which has more volatility and risk, PRQR or MREO?

Does the media refer more to PRQR or MREO?

Do institutionals & insiders have more ownership in PRQR or MREO?

Which has higher earnings & valuation, PRQR or MREO?

Is PRQR or MREO more profitable?

Summary

How does Mereo BioPharma Group compare to Voyager Therapeutics?

Do insiders and institutionals believe in MREO or VYGR?

Which has more volatility and risk, MREO or VYGR?

Does the media favor MREO or VYGR?

Do analysts prefer MREO or VYGR?

Which has stronger valuation & earnings, MREO or VYGR?

Is MREO or VYGR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools